Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for Cynthia M. Russell�
4.03
-0.02 (-0.49%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.91 - 4.21
52 week 1.68 - 6.95
Open 4.02
Vol / Avg. 2.77M/5.25M
Mkt cap 842.50M
P/E     -
Div/yield     -
EPS -0.30
Shares 209.06M
Beta 2.13
Inst. own 56%
May 5, 2014
Q1 2014 Novavax Earnings Release (Estimated) Add to calendar
Apr 9, 2014
Novavax at Needham Healthcare Conference
Mar 10, 2014
Q4 2013 Novavax Earnings Conference Call
Mar 10, 2014
Q4 2013 Novavax Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -318.62% -129.13%
Operating margin -318.18% -134.38%
EBITD margin - -126.83%
Return on average assets -36.31% -33.75%
Return on average equity -42.94% -42.52%
Employees 137 -
CDP Score - -

Address

20 FIRSTFIELD ROAD
GAITHERSBURG, MD 20878
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 59
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 49
Bio & Compensation  - Reuters
Cynthia N. Oliver Ph.D. Senior Vice President - Process Development Operations
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Russell P. Wilson JD Senior Vice President - Business Development
Age: 53
Bio & Compensation  - Reuters
Louis F. Fries Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
D. Nigel Thomas Vice President - Clinical Operations
Bio & Compensation  - Reuters